NS5a Replication Complex Inhibitor Will Be Used in Future Studies

Share

Follow Us

Print this page

Medivir: Janssen Has Acquired an NS5a Replication Complex Inhibitor That Will Be Evaluated with Simeprevir in Future Clinical Development

STOCKHOLM, Sweden–(BUSINESS WIRE)–October 08, 2013–

Regulatory News:

Medivir AB (OMX: MVIR) announced that Janssen Pharmaceuticals, Inc. (Janssen) has acquired the investigational compound GSK2336805 (GSK805), an NS5a replication complex inhibitor in phase II development for the treatment of chronic hepatitis C. Janssen has acquired all rights to develop and commercialize GSK2336805 including in combination with other drugs. Janssen acquired the compound from an affiliate of GlaxoSmithKline plc, financial details of the agreement have not been disclosed.

Janssen plans to initiate phase II studies to evaluate the use of GSK805 in interferon-free combinations with simeprevir (TMC435) and TMC647055, Janssen’s non-nucleoside polymerase inhibitor, for the treatment of chronic hepatitis C in adult patients with compensated liver disease.

Continue reading this entire article:
http://online.wsj.com/article/PR-CO-20131008-906189.html

Download Our Free Reports

Inside you'll discover:

• Things You May Not Know About Hepatitis C
• 7 Liver Detox SUPER Foods Your Doctor Isn't Telling You About
• 5 Dangerous Foods That Will Wreak Havoc On Your Liver
• A free "Mystery" Gift Valued at $9.99

Email address

Download Now

You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.